Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.

The Key to Connecting with Patients: Pharma's Market Access Transformation

How pharma can productively coexist with PBMs—and still lower drug costs faster.

Working with the Middle

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.

The Next Era of Drug Safety is in Intelligent Action

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - December 2025

Managing partner at Numerof & Associates.

Articles

Community pharmacies are being squeezed out of local markets, creating pharmacy deserts that raise costs, reduce access, and strain the healthcare system.

The Broken Business Model Driving America’s Pharmacy Deserts

. He can be reached at nsaraceno@mjhlifesciences.com.

SQ Innovation’s at-home furosemide injection for heart failure–related edema is now available through two of the Big Three drug wholesalers and covered under a Medicaid rebate agreement, expanding access for hospitals, pharmacies, and eligible patients.

Lasix ONYU Gains Major Distributor Access Through Cardinal Health and Cencora

These hubs can streamline access, reduce friction across reimbursement and logistics, and improve outcomes, as the CGT pipeline expands and patient demand accelerates.

Designing Patient Hubs Purpose-Built for Cell and Gene Therapies

TrumpRx is meant to reduce drug costs, but Americans are wondering how it works and what impact it will have.

Everything to Know About TrumpRx in 2026

Podcasts

In today’s Pharma Pulse, TrumpRx officially goes live, while Novo Nordisk prepares to take the oral version of Wegovy to the biggest stage in advertising.

Pharma Pulse: TrumpRx Takes Flight and Novo Nordisk’s Super Bowl Gambit

What 2025 means for the life sciences sector in the New Year.

Pharma's Year of Two Halves 

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

TrumpRx Launches With MFN-Based Drug Discounts 

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

The Great Repricing: Commercial Channel Under Pressure

Senior Vice President, Market Development, at ConnectiveRx.

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

Your Copay Program Is Protecting Access. Is It Also Protecting Gross-to-Net?

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

Featured Content

The Key to Connecting with Patients: Pharma's Market Access Transformation

Working with the Middle

The Next Era of Drug Safety is in Intelligent Action

Pharmaceutical Commerce - December 2025